Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon

NACompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

October 13, 2014

Primary Completion Date

June 10, 2020

Study Completion Date

June 10, 2020

Conditions
Primary Raynaud's Phenomenon (PR)Genetic Mutations Causing PRStudy of Patients and Their Relatives (With or Without Primary PR)
Interventions
GENETIC

Demonstration of genetic mutations causing Raynaud's phenomenon

"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.~Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.~The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."

Trial Locations (6)

44000

CHU de NANTES - Service de Médecine Interne, Nantes

44600

Ch Saint Nazaire, Saint-Nazaire

49033 Angers Cedex 01

CHU Angers - Service d'Explorations vasculaires, Angers

29609 Brest Cedex 2

CHRU HOPITAL CAVALE BLANCHE - Service de Médecine vasculaire, Brest

85925 La Roche/Yon Cedex 9

CHD La Roche sur Yon - Service Angéiologie, La Roche-sur-Yon

35203 Rennes Cedex 2

C.H.R. HOPITAL SUD - Service de Médecine interne, Rennes

All Listed Sponsors
lead

Nantes University Hospital

OTHER

NCT02202291 - Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon | Biotech Hunter | Biotech Hunter